Drugs / ATH-1020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05169671 | Mar → Sep 2022 | — | LeonaBio | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-11-16 | LeonaBio | Results Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference leonabio.com ↗
Two small molecule positive modulators of the HGF/MET pathway, ATH-1018 and ATH-1020, significantly reduced measures of pain in a streptozotocin (STZ)-induced rat model of diabetic neuropathy. |
| 2022-03-02 | LeonaBio | Results Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting leonabio.com ↗
In two unique disease models, ATH-1020 reduces depression-like behaviors, and normalizes sensory processing deficits in schizophrenia |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATH-1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05169671 ↗ |
| Route | Oral | “ATH-1020 in oral capsule form” NCT05169671 ↗ |